EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Marked Response to Nivolumab by a Patient With SMARCA4 ‐Deficient Undifferentiated Urothelial Carcinoma Showing High PD ‐ L1 Expression: A Case Report

Yohei Arihara iD, Ginji Omori, Ko Kobayashi, Shintaro Sugita, Kazuyuki Murase, Tomohiro Kubo, Masashi Idogawa, Tadashi Hasegawa, Kohichi Takada

Cancer Reports · 2024

DOI: 10.1002/cnr2.2127 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Yohei Arihara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: DNA Helicases, Transcription Factors, Urinary Bladder Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SMARCA4 is a component gene of the SWI/SNF (SWItch/Sucrose NonFermentable) chromatin remodeling complex; undifferentiated tumors associated with its functional deletion have been described in several organs. However, no established treatment for these tumors currently exists. Case In this study, we report a case of a SMARCA4‐deficient undifferentiated urothelial carcinoma with high PD‐L1 expression that was effectively treated with nivolumab after early relapse following treatment for non‐invasive bladder cancer. The histological morphology of the rhabdoid‐like undifferentiated tumor of unknown primary led us to suspect a SWI/SNF‐deficient tumor, and subsequent immunostaining led to the diagnosis of a SMARCA4‐deficient undifferentiated tumor. This effort also led to the identification of the developmental origin of this SMARCA4‐deficient undifferentiated tumor as a non‐invasive bladder cancer. We also carried out a detailed immune phenotypic assay on peripheral T cells. In brief, a phenotypic change of CD8+T cells from naive to terminally differentiated effector memory cells was observed.

Conclusion

Regardless of the organ of cancer origin or cancer type, SWI/SNF‐deficient tumors should be suspected in undifferentiated and dedifferentiated tumors, and immune checkpoint inhibitors may be considered as a promising treatment option for this type of tumor. The pathogenesis of SMARCA4‐deficient anaplastic tumors awaits further elucidation for therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA HelicasesTranscription FactorsUrinary Bladder NeoplasmsB7-H1 AntigenNuclear ProteinsNivolumabHumansMaleCarcinoma, Transitional CellAgedTreatment Outcome

Stichwörter der Autor:innen

SMARCA4carcinoma of unknown primaryimmune checkpoint inhibitornivolumab

Substanzen

SMARCA4 protein, humanDNA HelicasesTranscription FactorsCD274 protein, humanB7-H1 AntigenNuclear ProteinsNivolumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Medical Genome Sciences, Cancer Research Institute, Sapporo Medical University School of Medicine, Sapporo, Japan.

ORCID-Profile: Yohei Arihara

Zitieren

APA

Arihara, Y., Omori, G., Kobayashi, K., Sugita, S., Murase, K., Kubo, T., Idogawa, M., Hasegawa, T., & Takada, K. (2024). Marked Response to Nivolumab by a Patient With SMARCA4 ‐Deficient Undifferentiated Urothelial Carcinoma Showing High PD ‐ L1 Expression: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.2127

Vancouver

Arihara Y, Omori G, Kobayashi K, Sugita S, Murase K, Kubo T, et al. Marked Response to Nivolumab by a Patient With SMARCA4 ‐Deficient Undifferentiated Urothelial Carcinoma Showing High PD ‐ L1 Expression: A Case Report. Cancer Reports. 2024. doi:10.1002/cnr2.2127

BibTeX
@article{Arihara2024,
  author = {Arihara, Yohei and Omori, Ginji and Kobayashi, Ko and Sugita, Shintaro and Murase, Kazuyuki and Kubo, Tomohiro and Idogawa, Masashi and Hasegawa, Tadashi and Takada, Kohichi},
  title = {Marked Response to Nivolumab by a Patient With SMARCA4 ‐Deficient Undifferentiated Urothelial Carcinoma Showing High PD ‐ L1 Expression: A Case Report},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2127}
}
Kostenlos starten →